Track BillionToOne, Inc. Class A Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

BillionToOne, Inc. Class A Common Stock BLLN · Stock Open BillionToOne, Inc. Class A Common Stock in new tab

105.15 USD
P/E
114.29
EPS
0.92
P/B
8.84
ROE
13.23
Target Price
128.29 USD
BillionToOne, Inc. Class A Common Stock logo

BillionToOne, Inc. Class A Common Stock

🧾 Earnings Recap – Q1 2026

BillionToOne’s stock surged 16.3% following an earnings report that impressed investors with outsized revenue growth, significant test volume expansion, and margin expansion, signaling confidence in the company’s high-growth trajectory and innovative product pipeline.

  • Total revenue grew 84% year over year, driven by a 44% increase in test volume.
  • Average selling prices rose 28% to $571 per test, supporting gross margin expansion to 73%, up 9 percentage points year over year.
  • Cost of goods sold remained controlled at $153 per test despite a higher mix of oncology tests with typically higher COGS.
  • The company reported a strong profitability profile with a 16% GAAP operating margin and 24% adjusted EBITDA margin.
  • Recent market developments include the launch of Unity Confirm, a novel noninvasive fetal cell-based confirmation test addressing a critical clinical need, alongside progress on oncology product launches and network coverage expansion to 300 million U.S. lives.
📅
Loading chart...
Key Metrics
Earnings dateMarch 10, 2027
P/E114.29
EPS0.92
Book Value11.89
Price to Book8.84
Debt/Equity24.79
% Insiders28.629%
Growth
Revenue Growth0.47%
Earnings Growth2.20%
Estimates
Forward P/E66.97
Forward EPS1.57
Target Mean Price128.29

DCF valuation

Model fair value for BillionToOne, Inc. Class A Common Stock (BLLN)
Result
Sign in to run the valuation for BLLN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Strong buy · mean target 128.29 USD (low 110.00, high 145.00) · as of 15 Nov 2026
Low 110.00
Mean 128.29
High 145.00
Price 105.15
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

BillionToOne, Inc. Class A Common Stock Logo BillionToOne, Inc. Class A Common Stock Analysis (BLLN)

USA Official Website Stock

Is BillionToOne, Inc. Class A Common Stock a good investment? BillionToOne, Inc. Class A Common Stock (BLLN) is currently trading at 105.15 USD. Market analysts have a consensus price target of 128.29 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 114.29. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: BillionToOne, Inc. Class A Common Stock is expected to release its next earnings report on March 10, 2027. The market consensus estimate for Forward EPS is 1.57.

Investor FAQ

Does BillionToOne, Inc. Class A Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is BillionToOne, Inc. Class A Common Stock?

BillionToOne, Inc. Class A Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 10, 2027. The company currently has a trailing EPS of 0.92.

Company Profile

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Exchange Ticker
US BLLN
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion